Floatz logo

Sugemalimab

Refractory Malignant Neoplasm

Second Affiliated Hospital of Soochow Universitymonoclonal_antibodyPhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

171 Active assets in the Refractory Malignant Neoplasm cohort.

Asset / SponsorPhaseRating
Catequentinib
Nanfang Hospital, Southern Medical University
Phase 3BB
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Durvalumab
OHSU Knight Cancer Institute
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Nivolumab
CatalYm GmbH
Phase 2BB

View all 50 →

Same molecule, other indications

Sugemalimab is also rated in:

small cell lung carcinomaActive
BB
Indicative · Phase 2/3
64 / 100
View asset →
non-small cell lung carcinomaActive
B
Indicative · Phase 3
63 / 100
View asset →
extranodal nasal NK/T cell lymphomaActive
B
Indicative · Phase 3
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →